Inclisiran + Matching Placebo for Inclisiran
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Hypercholesterolemia or Mixed Dyslipidemia
Conditions
Primary Hypercholesterolemia or Mixed Dyslipidemia
Trial Timeline
Jul 11, 2023 → Oct 24, 2024
NCT ID
NCT05888103About Inclisiran + Matching Placebo for Inclisiran
Inclisiran + Matching Placebo for Inclisiran is a phase 3 stage product being developed by Novartis for Primary Hypercholesterolemia or Mixed Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05888103. Target conditions include Primary Hypercholesterolemia or Mixed Dyslipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05888103 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Hypercholesterolemia or Mixed Dyslipidemia